Aviv Pharma Acquires Nostrum's Fioricet Generic ANDA 075929 for $600,000.
Restructuring of the Generic Market and Asset Acquisition
Nostrum Laboratories, Inc., a former U.S. generic drug manufacturer, underwent bankruptcy proceedings, leading to the acquisition of its ANDA 075929 asset, a generic version of butalbital/acetaminophen/caffeine/codeine phosphate combination drug, by Aviv Pharma Inc. This transaction, which occurred during Nostrum's Chapter 11 liquidation auction, involved an upfront payment of $600,000. By acquiring a marketed asset with regulatory approval, Aviv Pharma can diversify its portfolio without incurring additional clinical trial or regulatory approval risks.
Therapeutic Value of a Multi-Mechanism Combination Drug
The acquired ANDA 075929 is a generic product that has demonstrated bioequivalence to AbbVie's Fioricet with Codeine. This combination drug contains acetaminophen, which inhibits pain transmission; butalbital, a barbiturate that depresses the central nervous system; caffeine, which constricts blood vessels; and codeine phosphate, a potent opioid analgesic. These four components work synergistically to relieve tension headaches. Although the combination of ingredients offers superior efficacy compared to single-agent drugs, it contains an opioid component, which carries a high risk of dependence and abuse.
Strengthening Regulations and Declining Market Trends
Fioricet-related drugs have been a mainstay in the headache treatment market, with over 3 million prescriptions annually. However, due to stricter regulations on misuse and safety concerns, the market size is gradually shrinking. The U.S. market sales for this combination drug were approximately $150 million annually in the past but are projected to decline to $90 million by 2028. The FDA has implemented strict Risk Evaluation and Mitigation Strategies (REMS), including limiting the daily dose of acetaminophen, which can cause acute liver failure, and attaching a boxed warning to codeine due to its high potential for addiction.
Competitive Landscape and Future of the Portfolio
In the current tension headache and migraine market, innovative CGRP (calcitonin gene-related peptide) inhibitors, such as Pfizer's Nurtec ODT and AbbVie's Ubrelvy, are rapidly gaining market share. In this market environment, Aviv Pharma's acquisition of Nostrum's older combination drug is a strategic move to maintain a niche market that can serve as a cash cow rather than competing in the development of new drugs. Although the market is in a mature stage with slowing growth, there is still a consistent demand, so a business model that maximizes operational efficiency to secure margins is expected.
This acquisition is considered an efficient capital allocation case, as Aviv Pharma secured an approved marketed portfolio through the sale of bankruptcy assets for only $600,000. Aviv Pharma will immediately gain revenue and market share in the existing Fioricet generic market, which previously had 3 million prescriptions and $150 million in sales annually. In the medium to long term, however, there are risks, including competition with new CGRP inhibitors such as Pfizer's Nurtec ODT and the FDA's strengthening regulations on opioid analgesics (REMS), which could reduce the overall market to $90 million by 2028. Therefore, investors and industry stakeholders should view the ability to reduce production costs in response to strengthening regulations and maintain margins in niche markets as key competitive advantages.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=ANDA075929